vs
Side-by-side financial comparison of COMERICA INC (CMA) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
COMERICA INC is the larger business by last-quarter revenue ($838.0M vs $699.9M, roughly 1.2× QuidelOrtho Corp). COMERICA INC runs the higher net margin — 21.0% vs -104.7%, a 125.7% gap on every dollar of revenue. On growth, COMERICA INC posted the faster year-over-year revenue change (3.3% vs -3.7%). Over the past eight quarters, COMERICA INC's revenue compounded faster (108.9% CAGR vs -2.9%).
Comerica Incorporated is an American financial services company, headquartered in Dallas, Texas. It is the parent of Comerica Bank, a regional commercial bank with 413 branches in the U.S. states of Texas, Michigan, California, Florida and Arizona. Comerica is among the largest U.S. financial holding companies, with offices in a number of U.S. cities.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
CMA vs QDEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0M | $699.9M |
| Net Profit | $176.0M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | — | -100.7% |
| Net Margin | 21.0% | -104.7% |
| Revenue YoY | 3.3% | -3.7% |
| Net Profit YoY | -4.3% | -3583.4% |
| EPS (diluted) | $1.35 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $838.0M | $699.9M | ||
| Q2 25 | $849.0M | $613.9M | ||
| Q1 25 | $829.0M | $692.8M | ||
| Q4 24 | $825.0M | $707.8M | ||
| Q3 24 | $811.0M | $727.1M | ||
| Q2 24 | $824.0M | $637.0M | ||
| Q1 24 | $784.0M | $711.0M | ||
| Q4 23 | $192.0M | $742.6M |
| Q3 25 | $176.0M | $-733.0M | ||
| Q2 25 | $199.0M | $-255.4M | ||
| Q1 25 | $172.0M | $-12.7M | ||
| Q4 24 | $170.0M | $-178.4M | ||
| Q3 24 | $184.0M | $-19.9M | ||
| Q2 24 | $206.0M | $-147.7M | ||
| Q1 24 | $138.0M | $-1.7B | ||
| Q4 23 | $33.0M | $7.0M |
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% | ||
| Q4 23 | — | 5.4% |
| Q3 25 | 21.0% | -104.7% | ||
| Q2 25 | 23.4% | -41.6% | ||
| Q1 25 | 20.7% | -1.8% | ||
| Q4 24 | 20.6% | -25.2% | ||
| Q3 24 | 22.7% | -2.7% | ||
| Q2 24 | 25.0% | -23.2% | ||
| Q1 24 | 17.6% | -239.9% | ||
| Q4 23 | 17.2% | 0.9% |
| Q3 25 | $1.35 | $-10.78 | ||
| Q2 25 | $1.42 | $-3.77 | ||
| Q1 25 | $1.25 | $-0.19 | ||
| Q4 24 | $1.22 | $-2.54 | ||
| Q3 24 | $1.33 | $-0.30 | ||
| Q2 24 | $1.49 | $-2.20 | ||
| Q1 24 | $0.98 | $-25.50 | ||
| Q4 23 | $0.20 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | $5.4B | $2.5B |
| Stockholders' EquityBook value | $7.4B | $2.0B |
| Total Assets | $77.4B | $5.7B |
| Debt / EquityLower = less leverage | 0.73× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M | ||
| Q4 23 | — | $167.3M |
| Q3 25 | $5.4B | $2.5B | ||
| Q2 25 | $5.8B | $2.1B | ||
| Q1 25 | $5.7B | $2.1B | ||
| Q4 24 | $6.7B | $2.1B | ||
| Q3 24 | $6.8B | $2.2B | ||
| Q2 24 | $7.1B | $2.2B | ||
| Q1 24 | $7.1B | $2.2B | ||
| Q4 23 | $6.2B | $2.3B |
| Q3 25 | $7.4B | $2.0B | ||
| Q2 25 | $6.9B | $2.8B | ||
| Q1 25 | $7.1B | $3.0B | ||
| Q4 24 | $6.5B | $3.0B | ||
| Q3 24 | $7.4B | $3.2B | ||
| Q2 24 | $6.2B | $3.2B | ||
| Q1 24 | $6.0B | $3.3B | ||
| Q4 23 | $6.4B | $5.0B |
| Q3 25 | $77.4B | $5.7B | ||
| Q2 25 | $78.0B | $6.4B | ||
| Q1 25 | $77.6B | $6.5B | ||
| Q4 24 | $79.3B | $6.4B | ||
| Q3 24 | $79.7B | $6.8B | ||
| Q2 24 | $79.6B | $6.7B | ||
| Q1 24 | $79.4B | $6.7B | ||
| Q4 23 | $85.8B | $8.6B |
| Q3 25 | 0.73× | 1.23× | ||
| Q2 25 | 0.84× | 0.74× | ||
| Q1 25 | 0.81× | 0.70× | ||
| Q4 24 | 1.02× | 0.72× | ||
| Q3 24 | 0.92× | 0.68× | ||
| Q2 24 | 1.15× | 0.70× | ||
| Q1 24 | 1.18× | 0.68× | ||
| Q4 23 | 0.97× | 0.45× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-270.0M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | -1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-270.0M | $-45.5M | ||
| Q2 25 | $476.0M | $-46.8M | ||
| Q1 25 | $273.0M | $65.6M | ||
| Q4 24 | $601.0M | $63.7M | ||
| Q3 24 | $1.0B | $117.9M | ||
| Q2 24 | $111.0M | $-97.9M | ||
| Q1 24 | $-205.0M | $-700.0K | ||
| Q4 23 | $1.1B | $80.4M |
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M | ||
| Q4 23 | — | $31.8M |
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% | ||
| Q4 23 | — | 4.3% |
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% | ||
| Q4 23 | — | 6.5% |
| Q3 25 | -1.53× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 5.70× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | -1.49× | — | ||
| Q4 23 | 34.00× | 11.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMA
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
